A new experimental vaccine may offer fresh hope for people with certain aggressive brain cancers that have long been difficult to treat.
Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital and several partner institutions have reported encouraging long-term results from an early clinical trial.
The findings were published in Nature Cancer and suggest that teaching the immune system to recognize a specific tumor mutation could help patients live much longer than expected.
Gliomas are among the most common types of brain tumors in adults. They are difficult to remove completely because cancer cells often spread into nearby brain tissue.
Even after surgery, radiation therapy and chemotherapy, the tumors frequently grow back. Because of this, scientists have spent many years searching for treatments that can target the cancer more precisely without harming healthy brain cells.
The new vaccine focuses on a genetic change found in many gliomas. A mutation in the IDH1 gene changes the structure of a protein inside cancer cells.
This altered protein helps the tumor grow, but it also makes the cancer cells look different from healthy cells. Researchers realised this unique feature could allow the immune system to identify and attack the tumor while leaving normal tissue alone.
The research team created a peptide vaccine designed to train the immune system to recognise this abnormal protein.
The vaccine was tested in a phase 1 clinical trial called NOA-16 involving 33 people with newly diagnosed high-grade astrocytomas, the most common type of glioma carrying this mutation. All participants also received standard treatment including surgery, chemotherapy and radiation therapy.
The long-term results were particularly encouraging. After up to eight years of follow-up, 66 percent of participants were still alive. In 42 percent of patients, the cancer had not become worse during the observation period. These results compare favourably with previous studies in which many patients with more aggressive gliomas survived only about two and a half to five years on average.
The researchers found that patients with the strongest immune responses also had the best long-term outcomes. The vaccine activated both T cells, which directly attack cancer cells, and B cells, which produce antibodies. Strong and lasting antibody responses were especially linked with better survival.
The team also examined tumor samples and found that vaccine-activated immune cells had actually entered the tumors. These specialised T cells were detected only in patients whose tumors remained under control, suggesting the vaccine was working directly where it was needed most.
Early evidence suggests booster doses may strengthen the immune response even years after the first vaccination without causing additional safety problems. If confirmed, booster shots could help maintain protection against tumor growth over much longer periods.
The researchers emphasised that this was an early phase study mainly designed to assess safety and immune responses rather than prove effectiveness. Because there was no comparison group, the survival benefits cannot yet be attributed entirely to the vaccine. Larger randomised clinical trials are already being planned to answer this question more definitively.
In my view, this study represents one of the most promising advances in brain cancer immunotherapy in recent years. Instead of creating personalised vaccines for every patient, this approach targets a common mutation shared by many tumors, making widespread treatment more practical.
Although larger trials are essential before the vaccine becomes routine care, the impressive long-term survival results provide genuine optimism for patients facing one of the most difficult cancers to treat.
If you care about cancer, please read studies about how to fight cancer with these anti-cancer superfoods ,and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about how to harness the power of anti-cancer foods and supplements, and cancer-fighting foods and recipes.
Source: German Cancer Research Center (DKFZ).
